Condition: NSCLC (Non-small Cell Lung Cancer) · Non-Small Cell Lung Cancer · NSCLC · Sponsor: Revolution Medicines, Inc.
The purpose of this study is to evaluate the safety and efficacy of a novel RAS(ON) inhibitor compared to docetaxel.
This description comes directly from the study's public registry record.
Revolution Medicines Study Director · 1-844-2-REVMED · medinfo@revmed.com
Always discuss trial participation with your own doctor first.
| Alabama Oncology | Birmingham, Alabama, United States | Recruiting |
| MemorialCare Long Beach Medical Center | Long Beach, California, United States | Recruiting |
| Yale University, Smillow Cancer Center | New Haven, Connecticut, United States | Recruiting |
| Florida Cancer Specialists & Research Institute - South | Fort Myers, Florida, United States | Recruiting |
| BRCR Global | Plantation, Florida, United States | Recruiting |
| Cancer Care Centers of Breevard | Rockledge, Florida, United States | Recruiting |
| Florida Cancer Specialists & Research Institute - North | St. Petersburg, Florida, United States | Recruiting |
| Cleveland Clinic Martin North | Stuart, Florida, United States | Recruiting |
| Florida Cancer Specialists & Research Institute - East | West Palm Beach, Florida, United States | Recruiting |
| University Cancer and Blood Center | Athens, Georgia, United States | Recruiting |
| Piedmont Healthcare, Inc | Atlanta, Georgia, United States | Recruiting |
| Winship Cancer Institute | Atlanta, Georgia, United States | Recruiting |
+ 140 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06881784